(Date:11/22/2008)...10 don,t do enough to protect themselves from stro...HealthDay News) -- It,s one of medicine,s mantras:...lower it will have a dramatic impact on your risk ...cent of people with high blood pressure still aren...ng to a U.S. Centers for Disease Control and Preve...
(Date:11/21/2008)...UNTY, Calif., Nov. 21 Album Creati...irm, launches a new program offering big brand mar...aken the large, expensive ad agency process and se... a very hands-on approach," says Matt Parker, Crea... combines experience and proven brand-building tec...
(Date:11/21/2008)...HASSEE, Fla. -- A Florida State University College...s discovered an important new layer of regulation ...greater understanding of the way cancer begins. ,...ces at the College of Medicine, said the findings ...r and could lead to the design of new drugs that k...
(Date:11/21/2008)...riz., Nov. 21 The Provid...announced that Craig A. Norris, the Company,s,Chi...mpany,s Board of,Directors. Mr. Norris, appointm...gnation of Steven I. Geringer and returns the boar...ny committee of the Board. , Mr. Norris, ag...
Breaking Medicine News(10 mins):Health News:High Blood Pressure Stalks Many Americans 2Health News:High Blood Pressure Stalks Many Americans 3Health News:Album Creative Studios Tailors Big Brand Marketing For Small Businesses 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3(Date:11/20/2008)... Epeius Biotechnologies,announced today the resul...motherapy-resistant metastatic soft tissue sarcoma...awla, principal investigator, at the CTOS 14th,an... 2008. Patients received,repeated infusions of Re...of,safety and efficacy data showed no major toxic...
(Date:11/20/2008)...HASE III TRIAL SHOW SIGNIFICANT, DECREASES IN...ON, IN, FIBROMYALGIA P...lgium, Nov. 20 /PRNewswire-FirstCall/,-- Jazz Pha...next Brussels: UCB),announced today positive prel...ase III pivotal clinical trials of sodium oxybate ...
(Date:11/20/2008)...Call/ -- Duska Therapeutics,Inc., (OTC Bulletin ...d its,pivotal Phase 3 ATPace clinical trial proto...t (SPA) procedure with the U.S. Food and Drug Admi... agreement with the FDA, Duska intends to initiate...trolled and randomized Phase 3,clinical trial wit...
(Date:11/20/2008).../ -- The Scandinavian-based drug,development comp...es on its,lead antimicrobial candidate LTX-109. P...showed that the novel lytic peptidomimetic has an ...etter towards killing Staphylococcus,aureus and S...drugs. In,addition to this it has proven effectiv...
Breaking Medicine Technology:Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 3Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 4Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 5Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 6Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2CellCyte Genetics Corp Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases 3175 1CellCyte Genetics Corp Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases 3175 2CellCyte Genetics Corp Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases 3175 3AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 1AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 2AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 3AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 4MGT Capital Investments Inc Announces Subsidiarys Preliminary Agreement to Acquire Maydeal com 11485 1MGT Capital Investments Inc Announces Subsidiarys Preliminary Agreement to Acquire Maydeal com 11485 2HLTH Corporation Update 11482 1HLTH Corporation Update 11482 2HLTH Corporation Update 11482 3HLTH Corporation Update 11482 4HLTH Corporation Update 11482 5HLTH Corporation Update 11482 6HLTH Corporation Update 11482 7HLTH Corporation Update 11482 8HLTH Corporation Update 11482 9HLTH Corporation Update 11482 10HLTH Corporation Update 11482 11HLTH Corporation Update 11482 12HLTH Corporation Update 11482 13...HE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 27, 2007...ny involved in the,development and commercializati...ns at the 5th International Society for Stem Cell,...and, Australia,from June 17-20 and at the 13th Ann...lar Therapy (ISCT) in Sydney, Australia from June,...
...EW YORK--(BUSINESS WIRE)--Jun 27, 2007 - Gentium S... both clinical and preclinical,data that support t...sm of action of Defibrotide in combination with an...s presented both an update,from the Company,s ongo...fractory or relapsed multiple myeloma with Defibro...
Other Medicine Technology:Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice 2Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice 3Gentium's Defibrotide Seen as Active in Multiple Myeloma 2Gentium's Defibrotide Seen as Active in Multiple Myeloma 3Supplied sterile in peel-open packages. Intended for one-time use.
Used when establishing a percutaneous tract for nephrostomy drainage. The wire guide has an extra stiff shaft and a gradual transition to a very flexible tip. Supplied sterile in peel-open packages.
Supplied sterile in peel-open packages. Intended for one-time use.
Supplied sterile in peel-open packages. Intended for one-time use.
Medicine Products: